Onasemnogene abeparvovec-xioi (Zolgensma)

Zolgensma (onasemnogene abeparvovec‑xioi) is covered as a single lifetime IV dose for pediatric patients <2 years with SMA from bi‑allelic SMN1 mutations (excluded if ≥2 years, prior Zolgensma receipt, or failure to meet gene/titer criteria). Coverage requires documented SMN1 bi‑allelic mutation and SMN2 ≤3, baseline anti‑AAV9 titer ≤1:50, specialist prescription/consultation, pre‑treatment labs (LFTs, platelets, Troponin‑I), weight‑based dosing (1.1×10^14 vg/kg), a corticosteroid regimen equivalent to prednisolone 1 mg/kg/day starting 1 day before for 30 days, and discontinuation of ongoing Spinraza if applicable.

"Baseline anti-AAV9 antibody titer result showing ≤ 1:50"

Sign up to see full coverage criteria, indications, and limitations.